Podcast: Prof Gary Raskob speaks on dalteparin vs low-molecular-weight heparin/edoxaban for venous thromboembolism

21 Dec 2017
Professor Gary Raskob from the College of Public Health, University of Oklahoma, Oklahoma City, US speaks about the efficacy and safety of dalteparin vs low-molecular-weight heparin/edoxaban for venous thromboembolism in patients with cancer.
Editor's Recommendations